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Tumor suppressors block the development of cancer and are often lost during tumor development.
Papa et al. show that partial loss of normal PTEN tumor suppressor function can be compoundedby
additional disruption caused by the expression of inactivemutant PTENprotein. This has significant
implications for patients with PTEN gene mutations.If half of the cooks in a crowded kitchen
just wander around not doing any work,
the working cooks would almost certainly
work better without them. Similarly, in
biology, there are examples of mutant
proteins that interfere with the function
of their normal functional counterparts
within the same cells. In cancer biology,
perhaps the best recognized example of
this phenomenon is the p53 tumor sup-
pressor, in which partially inactive mutant
proteins aggravate tumor phenotypes
both through interference with normal
p53 when both proteins are present and
also through mechanisms independent
of p53 (Muller and Vousden, 2013). In
this issue of Cell, a new study of another
key tumor-suppressor protein establishes
this paradigm further in cancer biology
(Papa et al., 2014).
An important step in the development
of most cancers is the functional disrup-tion of proteins that have actions that nor-
mally inhibit tumor development, termed
tumor suppressors. PTEN is a tumor
suppressor that is frequently lost, either
partially or fully, from many sporadic
tumor types. A range of mechanisms
causes these losses of function, including
missense and truncation mutations and
deletions in and of the PTEN gene, as
well as reduced expression of active
PTEN mediated by promoter methylation,
the effects of miRNAs, and the suppres-
sion of PTEN enzyme activity (Leslie and
Foti, 2011). Loss of both copies of the
PTEN gene seems to lead to death during
embryonic development, but humans and
other vertebrates can survive carrying one
active and onemutant PTEN gene. Impor-
tantly, PTEN mutation carriers display a
diverse range of pathologies, including tu-
mor susceptibility, developmental abnor-
malities, and autism.The PTEN tumor suppressor appears
to act in a dose-dependent manner, and
in many tumors, loss of function appears
only partial (Alimonti et al., 2010; Carra-
cedo et al., 2011). Accordingly, it is not
uncommon to find evidence that cells
express both normal and inactive mutant
PTEN proteins, both in sporadic tumors
and throughout the body of individuals
who inherit one functional and onemutant
gene. The status of PTEN as a tumor sup-
pressor was established in part through
the study of several lines of transgenic
mice engineered to carry one wild-type
copy of Pten and one null allele that
expresses no active protein. These het-
erozygous mice develop a diverse range
of tumors, with substantial overlap with
the tumor spectrum observed in hu-
man PTEN mutation carriers and often
retaining some normal Pten expression
(Freeman et al., 2006; Knobbe et al.,157, April 24, 2014 ª2014 Elsevier Inc. 527
Figure 1. The Activity of Dimeric PTEN
A model for the action of dimeric PTEN to metabolize PIP3 at the plasma membrane and interference by inactive mutant (MUT) PTEN (red) forming weakly active
mixed dimers with the wild-type enzyme. Several factors remain to be determined definitively, including the fraction of cellular monomeric and dimeric PTEN and
their contributions to overall activity.2008). Papa et al. (2014) compare tumor
suppression in heterozygous mice car-
rying one normal Pten gene copy along-
side either a null deletion allele (often
written Pten+/) or a mutant allele en-
coding a mutant PTEN protein lacking
lipid phosphatase activity. Two different
mutant PTEN enzymes that have been
previously identified in tumors are studied
in this way: PTEN C124S, which lacks all
catalytic activity due to replacement
of the active site cysteine nucleophile,
and PTEN G129E, which lacks lipid phos-
phatase activity while retaining activity
against model protein substrates. Hetero-
zygous mice expressing either of these
stable mutant proteins (often written
Pten+/C124S and Pten+/G129E) develop
similar butmore severe tumor phenotypes
than mice simply lacking one functional
gene copy, which is consistent with previ-
ous observations of Pten+/G129E mice
(Wang et al., 2010). Phenotypes included
the development in around a third of
Pten+/C214S and Pten+/G129E mice of large
invasive mammary adenocarcinoma and
also a similar frequency of cerebellar
hypertrophy. This latter phenotype was
not observed in Pten+/ heterozygous
mice but is reminiscent of the human
condition Lhermitte-Duclos disease,
known to be associated with PTENmuta-
tions. This analysis provides strong sup-
port for the hypothesis that the diversity
of phenotypes observed in human PTEN528 Cell 157, April 24, 2014 ª2014 Elsevier Inmutation carriers may be related to
whether or not they express a stable inac-
tive mutant protein.
Studies to determine the mechanisms
by which mutant proteins affect tumor
phenotype first confirmed that hetero-
zygous knockin mice expressed levels of
Pten protein similar to normal mice car-
rying two functional copies of Pten rather
than the reduced level caused by having
one null copy. Functionally, PTENhas lipid
phosphatase activity that suppresses the
class I PI 3-kinase/AKT signaling network
by dephosphorylating phosphatidylinosi-
tol 3,4,5-trisphosphate (PIP3). Analysis of
the activation of the protein kinase Akt
confirms that loss of one normal Pten
gene copy causes a modest increase in
Akt phosphorylation relative to normal
cells. Importantly, a further modest in-
crease in phosphorylation is observed
both in tissues and primary cells derived
from the heterozygous knockin mice car-
rying one active and one inactive Pten
copy. This implies that the mutant Pten
proteins are able to interfere with the abil-
ity of the normal enzyme to metabolize its
PIP3 lipid substrate and is also consistent
with a significant role for the Akt kinases
in promoting the observed tumorigenesis.
The authors confirm their model by
an elegant analysis of the two PTEN
missense mutations most frequently
identified in tumors, R130G and R130Q.
Both mutant proteins are stable and actc.in a similar dominant-negative fashion as
C124S and G129E. The high frequency
of these mutations allows a valid analysis
of the phosphorylation of AKT in publicly
available data from 19 tumors harboring
these mutations and in which a strong
elevation is observed relative to tumors
simply lacking one PTEN allele.
To address the question of how the
inactive PTEN mutants interfere with the
action of the coexpressed normal PTEN
enzyme, the authors made the important
observation that a population of the
PTEN protein in cultured cells is present
as a dimer. They then follow up the possi-
bility that active PTEN protein function
may be blocked by heterodimerization
with inactive mutant protein. Although
the binding of the phosphorylated C-ter-
minal tail of PTEN to its phosphatase
and C2 domains has been well estab-
lished, this has generally been seen to
be an intramolecular autoinhibitory inter-
action (Odriozola et al., 2007; Rahdar
et al., 2009). In contrast, the observations
of Papa et al. (2014) seem to favor the
dimerization of unphosphorylated PTEN
in a catalytically active complex (Figure 1).
To confidently determine the fractions of
cellular PTEN in monomeric and dimeric
forms in different tissues, as well as
the precise form and potential regulation
of dimeric PTEN by phosphorylation
and other posttranslational modifications
such as ubiquitination, oxidation and
acetylation will take further work. How-
ever, this work raises the possibility that
most cellular PTEN is phosphorylated,
monomeric and autoinhibited, with a
small proportion being unphosphorylated
dimeric and active. On the other hand,
other potential dominant-negative mech-
anisms by which inactive mutant PTEN
may interfere with the functioning of the
normal protein can be envisaged, such
as competition as a monomer for bind-
ing to proteins involved in targeting the
enzyme optimally to its lipid substrate or
in posttranslational activation. The signifi-
cance of the dominant-negative effects
on tumor phenotype makes these impor-
tant questions to answer. A goal must be
that, in the future, the matching of treat-ments to patients may reflect knowledge
of the cellular effects of defined classes
of PTEN mutations.REFERENCES
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Knowing the copy number of cellular proteins is critical for understanding cell physiology. By being
able tomeasure the absolute synthesis rates of themajority of cellular proteins, Li et al. gain insights
into key aspects of translation regulation and fundamental principles of cellular strategies to adjust
protein synthesis according to the functional needs.Accurate accounting is the basis of an
efficient economy. In order to understand
the rules, trends, and directions of healthy
economic growth, one must be able to
track the precise amounts of individual
products generated, the demand for
these goods, and the strategies for allo-
cating the resources for their production.
In the cell, proteins are the main com-
modities. They control the majority of
cellular activity, but their production is
very expensive. Knowledge of how much
of each protein is made is therefore cen-
tral to understanding the organization,
growth, and proliferation of the cell.
As basic as knowing the copy number
of individual proteins in the cell mayseem, it is a difficult aim to achieve.
Althoughwhole-cell proteomics and other
genome-wide techniques provide useful
insights into changes in gene expression
under various physiological conditions,
estimating the absolute amounts of even
limited number of proteins is far more
challenging. In this issue of Cell, Li et al.
(2014) have succeeded in analyzing the
translation output of more than 3,000
E. coli genes and quantify production of
more than 95% of the proteins synthe-
sized in fast-growing cells.
The revolutionary ribosome profiling
technique developed by Weissman and
colleagues several years ago provides
a genome-wide view of translation of indi-vidual genes (Ingolia et al., 2009; Li et al.,
2012). The method is based on next-gen-
eration sequencing of the mRNA frag-
ments protected by ribosomes. Each
‘‘footprint’’ represents one translating
ribosome, which will most likely generate
one protein molecule encoded in the
respective gene (Figure 1A). Deep
sequencing of the ribosomal footprints
hence provides a snapshot of cellular pro-
tein synthesis and allows the estimation
of the fraction of ribosomes engaged
in translation of individual mRNAs and,
thus, the relative rate of expression of a
given gene. Normalizing this by the total
protein synthesized during the cell cycle
renders the absolute protein synthesis157, April 24, 2014 ª2014 Elsevier Inc. 529
